About us

The mission of ISCaM (ex ISPDC, International Society for Proton Dynamics in Cancer) is to improve communication and to foster collaborative activities and research programs between European and non European scientists engaged in acidity, proton dynamics, metabolism and microenvironment in cancer research.

ISCaM can consolidate, co-ordinate and facilitate International collaboration, facilitate translation of research to clinical development, and fundraise for Networking activities, scientific programs and projects, scientists mobility, young scientists grants and carrier programs.

Read ISCaM Statute at this link

Our Mission

Our mission is to advocate and effectively promote our approach to cancer therapy in the scientific community, social community, Funding Agencies, Governments, and stimulate translation into clinical applications.

  • To create a critical mass of scientists engaged in research activities on Metabolism in Cancer.
  • To gain visibility at National, European and International level.
  • To duly raise the necessary awareness of both the scientific community and society.
  • To attract resources to finance and conduct research in the field of metabolism in cancer.
  • To be recognized as an important counterpart for the European Commission, funding agencies and Industry.
  • To represent the main scientific stakeholder in the field.

ISCaM numbers

10 years of activities


Travel Grants Awarded




Annual meetings

Board members


Pawel Swietach


Professor of Physiology
Oxford University, UK

His laboratory at the Department of Physiology, Anatomy and Genetics investigates signalling by small molecules in the heart and in cancer, with a particular focus on hydrogen ions, which determine pH. His research focus on the understanding of the mechanisms by which cells handle their acidic products and how, in turn, acid/base chemistry affects biology.
Past president

Paolo Ettore Porporato


Associate professor
Department of Molecular Biotechnology and Health Sciences
University of Turin, Italy

Paolo E. Porporato currently works at the Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Università degli Studi di Torino. Paolo does research in Cell Biology, Cancer Research and Molecular Biology. Their current project is 'Targeting and treatment of cancer-associated cachexia and muscle atrophy'.

Alessandro Carrer


Group leader
Veneto Institute of Molecular Medicine (VIMM)
Padua, Italy

Alessandro investigates metabolic dependencies and their impact on epigenomic reprogramming during pancreatic carcinogenesis. He trained at University of Pennsylvania and his lab employs mouse transgenics to dissect metabolic and epigenomic perturbations that lead to tumor onset.

Elena Rainero


University of Sheffield, UK

Her laboratory studies the role of the extracellular matrix in controlling cancer cell metabolism. Elena recently demonstrated that starved breast cancer cells internalise and digest matrix components to sustain their proliferation. Her lab is now characterising the molecular mechanisms and the metabolic pathways regulating this process, to identify novel potential therapeutic targets. Her lab is also interested in defining the role of extracellular matrix remodelling and trafficking in controlling cancer cell invasion and metastasis.

Margherita Cortini


Tenure-track scientist
Department for Research, Innovation and Technology
Rizzoli Orthopaedic Specialty Hospital, Bologna, Italy

Margherita’s research focus is the understanding of the interaction between tumor and stromal cells and their reciprocal metabolic reprogramming during primary and metastatic tumor growth.

Board member 1

Cyril Corbet

Board member

FNRS Research Associate
Experimental and Clinical Research Institute
UC Louvain, Brussels, Belgium
His research group investigates the metabolism of therapy-resistant cancer cells (incl. cancer stem cells) and the interplay thereof with the tumor microenvironment in order to develop new targeted therapies overcoming conventional treatment escape.
Board member 2

Maria Rodriguez Colman

Board member

Associate professor
Center for Molecular Medicine (CMM)

Institute of Biomedical Sciences (IRB), Lleida, Spain
The Rodriguez Colman Lab investigates the "Metabolism of Stem Cells and Cancer" at the subcellular, cellular and tissue scale. To that end, they use organoids models, a multicellular and hetero-cellular system able to recapitulate the complexity of stem cell and differentiation dynamics. Organoids are derived from healthy adult, embryonic or cancer tissue. Next to research analysis of bioenergetics, metabolomics and other omics, they perform cutting-edge 4-D live imaging to gain insights of metabolic changes at different scales with temporal resolution. They introduce fluorescent based genetic reporters to monitor metabolism in different cellular compartments and cell type specification changes, and analyze these complex long-term live imaging data with machine learning based single cell tracking coupled to in-house analytical pipelines. Her lab investigates the molecular mechanisms by which metabolic changes drive cell fate decisions in health, development and disease.